To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

The human endogenous meta… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Contact form








 


Note! If you want an answer on a question you must specify your email address




The human endogenous metabolome as a pharmacology baseline for drug discovery

Journal article
Authors A. Bofill
X. Jalencas
Tudor I Oprea
J. Mestres
Published in Drug Discovery Today
Volume 24
Issue 9
Pages 1806-1820
ISSN 1359-6446
Publication year 2019
Published at Institute of Medicine, Department of Rheumatology and Inflammation Research
Pages 1806-1820
Language en
Links dx.doi.org/10.1016/j.drudis.2019.06...
Subject categories Endocrinology and Diabetes

Abstract

We have limited understanding of the variation in in vitro affinities of drugs for their targets. An analysis of a highly curated set of 815 interactions between 566 drugs and 129 primary targets reveals that 71% of drug–target affinities have values above that of the corresponding endogenous ligand, 96% of them fitting within a range of two orders of magnitude. Our findings suggest that the evolutionary optimised affinity of endogenous ligands for their native proteins can serve as a baseline for the primary pharmacology of drugs. We show that the degree of off-target selectivity and safety risks of drugs derived from their secondary pharmacology depend very much on that baseline. Thus, we propose a new approach for estimating safety margins. Two-thirds of drugs have more-potent in vitro affinities for their primary targets than those of the corresponding endogenous ligands, which define a baseline to estimate off-target safety margins. © 2019 Elsevier Ltd

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?